Exchange: NASDAQ·Updated 07:59 PM EDT

PCRX News

News
all
press releases
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Stocktwits
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Stocktwits
More News
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.read more...
Benzinga
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
Zacks
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
Pacira BioSciences secured a $1.65 billion buyout deal with Viatris, while Haemonetics expanded its CSL Plasma partnership, prompting BTIG to raise its price target.
Stocktwits
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday's regular session. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) stock rose 34.2% toread more...
Benzinga
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.read more...
Benzinga
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC. PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.PR NewswireMILWAUKEE, Oct. 8, 2026PCRX shareholders will receive just $36.50 per share in cash...
PR Newswire
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira soared 44.1% on Viatris acquisition news.read more...
Benzinga
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash.Halper Sadeh encourages Pacira shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary...
Business Wire
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain TherapiesPR...
PR Newswire

Advertisement|Remove ads.